NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Agilon Health, Inc. (NYSE: AGL) on behalf of long-term stockholders following a class action complaint that was filed against Agilon on March 19, 2024 with Class Period (1) Agilon common stock purchases traceable to the April 2021 initial public offering of Agilon stock; (2) pursuant, or traceable, or both, to materials issued in connection w ...

Magilon health, inc. (NYSE:AGL) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Leland Thomas - VP, IR Steven Sell - CEO Jeffrey Schwaneke - CFO Conference Call Participants Lisa Gill - JPMorgan Justin Lake - Wolfe Research Stephen Baxter - Wells Fargo Ryan Daniels - William Blair Elizabeth Anderson - Evercore ISI Adam Ron - Bank of America. Eduardo Ron - Truist George Hill - Deutsche Bank Michael Ha - Baird Jack Slevin - Jefferies Whit Mayo - Leerink Partners Jenny Shen - BT ...

Agilon Health (AGL) reported $1.48 billion in revenue for the quarter ended June 2024, representing a year-over-year increase of 29%. EPS of -$0.07 for the same period compares to -$0.04 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $1.56 billion, representing a surprise of -4.85%. The company has not delivered EPS surprise, with the consensus EPS estimate being -$0.07.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how th ...

Agilon Health (AGL) came out with a quarterly loss of $0.07 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.04 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this senior-focused health care company would post a loss of $0.02 per share when it actually produced earnings of $0.01, delivering a surprise of 150%.Over the last four quarters, the company has surpassed consensus EPS estimates just once.Agilon, which belo ...

FORM 10-Q _______________________________________________________ Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________ Delaware 37-1915147 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT T ...

Revenue Performance - Revenue increased 39% to $1.48 billion in Q2 2024 compared to $1.07 billion in Q2 2023[3] - Total revenues for the three months ended June 30, 2024, were $1,482,758, a 38.7% increase from $1,069,115 in the same period of 2023[21] - Medical services revenue for the six months ended June 30, 2024, reached $3,080,774, compared to $2,120,353 for the same period in 2023, reflecting a 45.4% growth[21] - Medical services revenue for Q2 2024 was $1,479,579, compared to $3,080,774 for the same period in 2023, indicating a significant decline in revenue[30] - Total revenues for Q2 2024 were $1,482,758, down from $3,087,112 in Q2 2023, marking a decrease of approximately 52%[30] Membership Growth - Medicare Advantage membership grew 38% to 513,000, while total members on the agilon platform increased 40% to 645,000[1][3] Financial Metrics - Medical margin was $106 million in Q2 2024, down 21% from $134 million in Q2 2023[4] - Adjusted EBITDA showed a loss of $3 million in Q2 2024, compared to earnings of $12 million in Q2 2023[4] - The company expects total revenues for FY 2024 to be between $6.01 billion and $6.04 billion[9] - For Q3 2024, total revenues are projected to be between $1.465 billion and $1.475 billion[10] - The company is maintaining its guidance for medical margin for FY 2024, expecting it to be between $400 million and $450 million[9] Cash and Assets - As of June 30, 2024, agilon health had cash and marketable securities totaling $408 million and total debt of $36 million[8] - Total current assets increased to $1,884,010 as of June 30, 2024, compared to $1,480,076 as of December 31, 2023, representing a growth of 27.3%[18] - Total assets increased to $2,163,315 as of June 30, 2024, from $1,740,866 as of December 31, 2023, representing a growth of 24.2%[18] - Cash and cash equivalents increased to $109,490 as of June 30, 2024, from $107,570 as of December 31, 2023[18] Expenses and Losses - Medical services expense for the three months ended June 30, 2024, was $1,374,060, up from $932,823 in the same period of 2023, reflecting a 47.4% increase[21] - Net loss attributable to common shares for the six months ended June 30, 2024, was $(36,746), compared to a loss of $(727) in the same period of 2023[21] - The company reported a net cash used in operating activities of $(66,493) for the six months ended June 30, 2024, compared to $(82,015) for the same period in 2023[22] - The company reported a net loss of $(30,662) for Q2 2024, compared to a net loss of $(16,795) in Q2 2023[29] Cost Management - Platform support costs for Q2 2024 were $41,687, a decrease from $42,041 in Q2 2023, while total general and administrative costs decreased to $69,612 from $79,254 year-over-year[26] - The company expects platform support costs to decrease over time as revenue grows and physician partners add members[26] - Geography entry costs for Q2 2024 were $4,866, down from $11,306 in Q2 2023, indicating a reduction in expansion-related expenses[26] Strategic Initiatives - The action plan includes improving payor relationships and increasing engagement among primary care physicians (PCPs)[6] - The company aims to onboard 75% of member data into its financial data pipeline by the end of 2024[7]

Investors can contact the law firm at no cost to learn more about recovering their losses. LOS ANGELES, June 10, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm is investigating potential claims against the board of directors of agilon health, inc. (“Agilon” or the “Company”) (NYSE: AGL). Agilon Health is a company focused on health care for seniors by partnering with primary care physicians. They provide support to help physicians, while also managing the administrative and financial aspects of care. If you ...

RADNOR, Pa., May 19, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against agilon health, inc. (NYSE: AGL) ("agilon" or the "Company").  This action, captioned Hope v. agilon health, inc., et al., Case No. 1:24-cv-00305, was filed in the United States District Court for the Western District of Texas and expanded the class period which was pled in a first-filed case in that same Court.  After the Hope ...

LOS ANGELES, May 16, 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against agilon health, inc. ("agilon" or the "Company") (NYSE: AGL).Class Period: April 15, 2021 – February 27, 2024Lead Plaintiff Deadline: May 20, 2024If you wish to serve as lead plaintiff of the agilon lawsuit, you can submit your contact information at https://www.glancylaw.com/cases/agilon-health-inc/. You can ...

Core Viewpoint - A class action lawsuit has been filed against Agilon Health, Inc. for alleged securities fraud and unlawful business practices, following significant financial disclosures that negatively impacted the company's stock price [1][4]. Financial Performance - Agilon conducted its initial public offering on April 15, 2021, selling over 53 million shares at $23.00 per share [2]. - In Q3 2023, Agilon reported medical margins of $108 million, significantly below analyst expectations, partly due to $9 million in previously unreported claims [3]. - The company experienced a $6 million loss in adjusted EBITDA for the quarter, which also missed analyst estimates, and lowered its 2023 expected medical margins [3]. - On January 5, 2024, Agilon revealed higher prior medical expenses, leading to a further reduction in its 2023 expected medical margin and a withdrawal of its 2026 guidance [4]. - For the year 2023, Agilon's medical margin was reported at just $299 million, falling short of the reduced range of $340 million to $360 million [5]. - The company slashed its 2024 medical margin guidance by 27% and adjusted EBITDA guidance from a projected gain of $40 to $60 million to a loss of $15 to $60 million [5]. Stock Price Impact - Following the Q3 2023 results announcement, Agilon's stock price fell by $2.23, or 13%, closing at $14.66 per share [3]. - After the January 5, 2024 announcement, the stock price dropped by $3.45, nearly 29%, closing at $8.63 per share [4]. - On March 1, 2024, after the disclosure of further financial issues, the stock price fell by $0.44, or 7%, closing at $6.04 per share, with subsequent declines reaching a low of $5.66 per share [5].